Survival and disease progression in UK patients with lymphangioleiomyomatosis. - Wikidata - awgldk - TriplyDB

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q34343897

about

Efficacy and safety of sirolimus in lymphangioleiomyomatosis."Getting stuck with LAM": patients perspectives on living with lymphangioleiomyomatosis.Diffuse Cystic Lung Disease. Part I.The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.Involvement of lymphatics in lymphangioleiomyomatosis Use of variability in national and regional data to estimate the prevalence of lymphangioleiomyomatosis.A quantitative proteomic approach to identify significantly altered protein networks in the serum of patients with lymphangioleiomyomatosis (LAM).Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.Lymphangioleiomyomatosis (LAM): molecular insights lead to targeted therapies.Lymphatics in lymphangioleiomyomatosis and idiopathic pulmonary fibrosis Predictors for clinical trial participation in the rare lung disease lymphangioleiomyomatosis.Wild type mesenchymal cells contribute to the lung pathology of lymphangioleiomyomatosis Lymphatic involvement in lymphangioleiomyomatosis Lymphangioleiomyomatosis - a wolf in sheep's clothing.Prevalence and Predictive Value of Dyspnea Ratings in Hospitalized Patients: Pilot Studies St. George's Respiratory Questionnaire has longitudinal construct validity in lymphangioleiomyomatosis Lymphangioleiomyomatosis and tuberous sclerosis complex.Multiple pneumothoraces during second and third trimesters as first presentation of lymphangioleiomyomatosis.A current viewpoint of lymphangioleiomyomatosis supporting immunotherapeutic treatment options.Renal angiomyolipoma and lymphangioleiomyomatosis in pregnancy.Familial syndromes associated with intracranial tumours: a review.The next breakthrough in LAM clinical trials may be their design: challenges in design and execution of future LAM clinical trials.Tuberous Sclerosis Complex: new criteria for diagnostic work-up and management.Clinical predictors of mortality and cause of death in lymphangioleiomyomatosis: a population-based registry.Experience of Lung Transplantation in Patients with Lymphangioleiomyomatosis at a Brazilian Reference Centre.Screening for lymphangioleiomyomatosis by high-resolution computed tomography in young, nonsmoking women presenting with spontaneous pneumothorax is cost-effective.[Chylothorax in an 87-year-old patient].Cystic Lung Disease in Genetic Syndromes with Deficient Tumor Suppressor Gene Function.Epidemiology of Rare Lung Diseases: The Challenges and Opportunities to Improve Research and Knowledge.Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.Clinical features of 280 hospitalized patients with lymphangioleiomyomatosis in Japan.Diagnosis of lymphangioleiomyomatosis in a 75-year-old woman.Computed tomography lymphangiography findings in 27 cases of lymphangioleiomyomatosis.Immunohistological features related to functional impairment in lymphangioleiomyomatosis.The epidemiology of lymphangioleiomyomatosis in Japan: A nationwide cross-sectional study of presenting features and prognostic factors The vitamin D binding protein axis modifies disease severity in lymphangioleiomyomatosis

P2860

Q24610039-ACE3D663-AA84-4649-9925-6AF145BB6118 Q33685049-341730E9-8E2B-479D-899E-9C6E1257B225 Q33722950-A115AFED-A12C-4641-A7F3-5BCB01B70C11 Q33905090-B7107252-5DD5-413C-BB41-A46973CEDBDE Q33905141-B4175FAE-D4F5-4F4F-A168-C0AE5BE322E5 Q33963293-F7600E0D-B28E-4ED1-8E49-596EF535912F Q34061748-C364E9BE-F8DF-4977-BDC1-2FB8482B1E63 Q34194187-5032DE57-D6F4-4906-9CE6-0C7E5379ECB7 Q34536450-1443D9F0-C3F7-4777-8451-127163FAEE99 Q34560457-BBAFB5A1-7310-4B64-B072-1CA404BD6FCA Q35531599-BF85FAAD-F120-486D-A389-980B0BE72893 Q35610828-064507C7-DC76-451E-9F13-E8BD9B82F695 Q36083291-FAA09DB0-5268-4B00-8172-48D022AB5DF2 Q36357766-84E83EF9-EFE3-417E-B3EC-FEA906836E2E Q36791250-375F839D-8A3B-4122-B5A5-A0E85BE33B58 Q36905344-1924BF93-91A8-49CC-8305-8BDADE121122 Q37137669-15F4DF3E-3617-475B-9BE7-888AE9F1FEB7 Q37186286-022EDC30-2A09-4826-B7F8-3C8EFF86D23A Q37937344-DCA67DD8-B30C-4536-AA50-7B8F173F0520 Q38126965-84F4AB4B-32A7-440C-AE4F-317B2E1D8DC3 Q38160164-D3D63B84-13BF-44F0-8FAF-614CCCE26BAB Q38372196-F8F48DE9-D956-47C6-9E26-52C2907FC33E Q38414596-50BCC6C9-0558-429D-A25A-02748A5F290F Q38463698-7512F623-AD04-4F2A-B95C-E3BD75D9148A Q38617379-106061DD-7864-4421-BF41-58DF00633F6D Q46493091-74FE5BDD-9789-46D5-ABD0-E21DA0453996 Q46850772-8E954E9A-FBE4-406A-BCA9-3CFE77D9EF4A Q47370738-B4B78155-0E47-4161-9617-7ADEAC822141 Q47656318-C062C1A6-CF1C-463A-8092-759D8D7CB305 Q48355779-F1BD2A3B-3DD6-48AB-A284-0EB99C91435A Q51684882-8FB117B7-D7FC-4C10-B71B-4DC558B5B9EA Q51709527-8256ADB4-AF36-4349-BDA3-29457BC60385 Q52953570-1CB6B32E-9256-4BC6-B008-679DC47C3CB1 Q54979000-7377932B-9C97-4509-9089-3545F273B33F Q55981832-35D63CC5-85E9-4C84-922D-F74A9402E5BB Q58701361-FD4E1D8A-897D-412E-A83A-2CFE4C220C56

P2860

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

http://www.wikidata.org/entity/Q34343897

description

2004 nî lūn-bûn

@nan

2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած

@hyw

2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված

@hy

2004年の論文

@ja

2004年論文

@yue

2004年論文

@zh-hant

2004年論文

@zh-hk

2004年論文

@zh-mo

2004年論文

@zh-tw

2004年论文

@wuu

name

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@ast

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@en

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@nl

type

label

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@ast

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@en

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@nl

prefLabel

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@ast

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@en

Survival and disease progression in UK patients with lymphangioleiomyomatosis.

@nl

P1433

Q34343897-FEE18E62-BDBA-44CA-924D-0FFFA029FCA4

P1476

Q34343897-DFCF472F-2F8F-4B9D-BBCA-F9FCEBF0E869

P2093

Q34343897-1346C45A-F8CF-4812-99BE-EA9D6299E7BB

Q34343897-96F89CF3-8FD0-451E-91E4-55F6C4287F65

Q34343897-9CEB4F6D-69BC-436F-9001-D73B7BBA03B5

Q34343897-C259F5AC-88E3-475A-BF5F-96A5500DFB07

P2860

Q34343897-24F536FF-1CB0-46AD-A6BB-95FE2EE1215C

Q34343897-3494330E-05FC-4F07-8A8A-C42AE58E4707

Q34343897-361DF8FF-4557-4FC6-BD7D-CFE7BC8F1B06

Q34343897-564F45E4-F9D8-4F27-A666-C3E78D69FED4

Q34343897-9390E672-9963-4BE4-B8C8-EF7C7DF0B456

Q34343897-9879E7DC-D0B7-466F-8C3B-0A9A485FB72E

Q34343897-A150185D-EC51-49B7-A872-EEE588A63137

Q34343897-ADAC826C-2FE8-4A9B-B07F-73266B0DDD6B

Q34343897-D4C119FA-D38C-482C-B77D-AA113C75C9B7

Q34343897-EB1C4B43-D422-4514-87B5-A2447D48E963

P304

Q34343897-738CFBC3-4198-4E1B-89D4-28683A76DBCC

P31

Q34343897-B85F3E8C-DF17-47B7-B085-5580CDC9F112

P356

Q34343897-CD0FC927-AA40-4A4D-892C-C5FD705C2EA4

P407

Q34343897-110014C8-7C3E-42ED-90CE-C26C7375A41D

P433

Q34343897-ED8EAA93-7DDD-44DF-A273-D5098E8D3549

P478

Q34343897-2892FF93-EC83-4317-8FCF-95D1700006C4

P50

Q34343897-014B311C-28B4-4400-99FC-D73996D7C104

P577

Q34343897-BFBACCFB-6FEB-4172-8CA0-35324AA81CB5

P5875

Q34343897-A0A91CC6-0652-4F94-BE43-77402E573556

P698

Q34343897-A886445F-8DD7-4C59-903E-EF367EFB4DA5

P921

Q34343897-BF23E304-4B53-4D86-851A-5AF7256D62DC

P932

Q34343897-D8431FC2-BB70-4ECF-A6CD-61A62FE1D598

P356

THX.2004.023283

P1433

P1476

Survival and disease progression in UK patients with lymphangioleiomyomatosis

@en

P2093

A E Tattersfield

http://www.w3.org/2001/XMLSchema#string

C I Whale

http://www.w3.org/2001/XMLSchema#string

R B Hubbard

http://www.w3.org/2001/XMLSchema#string

S A Lewis

http://www.w3.org/2001/XMLSchema#string

P2860

Rare diseases. 1. Lymphangioleiomyomatosis: clinical features, management and basic mechanisms

Pulmonary lymphangioleiomyomatosis. A study of 69 patients. Groupe d'Etudes et de Recherche sur les Maladies "Orphelines" Pulmonaires (GERM"O"P).

Pulmonary lymphangiomyomatosis. A review

Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease.

Clinical experience of lymphangioleiomyomatosis in the UK.

Lymphangioleiomyomatosis: a case-control study of perinatal and early life events.

Pregnancy and lymphangioleiomyomatosis: anaesthetic management.

Decline in lung function in lymphangioleiomyomatosis: relation to menopause and progesterone treatment.

John LIZARS. Centenary of a forgotten pioneer of the surgery of trigeminal neuralgia.

Pulmonary lymphangioleiomyomatosis: a report of 46 patients including a clinicopathologic study of prognostic factors.

P304

800-803

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/THX.2004.023283

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

59

http://www.w3.org/2001/XMLSchema#string

P50

Simon R. Johnson

P577

2004-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

8378245

http://www.w3.org/2001/XMLSchema#string

P698

15333859

http://www.w3.org/2001/XMLSchema#string

P921

P932

1747117

http://www.w3.org/2001/XMLSchema#string